|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Meoni G, Cecere FL, Lucherini E and Di
Costanzo F: Medical treatment of advanced non-small cell lung
cancer in elderly patients: A review of the role of chemotherapy
and targeted agents. J Geriatr Oncol. 4:282–290. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lin CW, Chang YL, Chang YC, Lin JC, Chen
CC, Pan SH, Wu CT, Chen HY, Yang SC, Hong TM and Yang PC:
MicroRNA-135b promotes lung cancer metastasis by regulating
multiple targets in the hippo pathway and LZTS1. Nat Commun.
4:18772013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Travis WD, Brambilla E and Riely GJ: New
pathologic classification of lung cancer: Relevance for clinical
practice and clinical trials. J Clin Oncol. 31:992–1001. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegelin MD and Borczuk AC: Epidermal
growth factor receptor mutations in lung adenocarcinoma. Lab
Invest. 94:129–137. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee YC and Light RW: Management of
malignant pleural effusions. Respirology. 9:148–156. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rami-Porta R, Bolejack V, Crowley J, Ball
D, Kim J, Lyons G, Rice T, Suzuki K, Thomas CF Jr, Travis WD, et
al: The IASLC lung cancer staging project: Proposals for the
revisions of the t descriptors in the forthcoming eighth edition of
the tnm classification for lung cancer. J Thorac Oncol.
10:990–1003. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ou SH, Zell JA, Ziogas A and Anton-Culver
H: Prognostic significance of the non-size-based AJCC T2
descriptors: Visceral pleura invasion, hilar atelectasis, or
obstructive pneumonitis in stage IB non-small cell lung cancer is
dependent on tumor size. Chest. 133:662–669. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Manac'h D, Riquet M, Medioni J, Le
Pimpec-Barthes F, Dujon A and Danel C: Visceral pleura invasion by
non-small cell lung cancer: An underrated bad prognostic factor.
Ann Thorac Surg. 71:1088–1093. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rami-Porta R, Bolejack V, Crowley J, Ball
D, Kim J, Lyons G, Rice T, Suzuki K, Thomas CF Jr, Travis WD, et
al: The IASLC lung cancer staging project: Proposals for the
revisions of the T descriptors in the forthcoming eighth edition of
the tnm classification for lung cancer. J Thorac Oncol.
10:990–1003. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kawase A, Yoshida J, Miyaoka E, Asamura H,
Fujii Y, Nakanishi Y, Eguchi K, Mori M, Sawabata N, Okumura M, et
al: Visceral pleural invasion classification in non-small-cell lung
cancer in the 7th edition of the tumor, node, metastasis
classification for lung cancer: Validation analysis based on a
large-scale nationwide database. J Thorac Oncol. 8:606–611. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yoshida J, Nagai K, Asamura H, Goya T,
Koshiishi Y, Sohara Y, Eguchi K, Mori M, Nakanishi Y, Tsuchiya R,
et al: Visceral pleura invasion impact on non-small cell lung
cancer patient survival: Its implications for the forthcoming TNM
staging based on a large-scale nation-wide database. J Thorac
Oncol. 4:959–963. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kudo Y, Saji H, Shimada Y, Nomura M,
Matsubayashi J, Nagao T, Kakihana M, Usuda J, Kajiwara N, Ohira T
and Ikeda N: Impact of visceral pleural invasion on the survival of
patients with non-small cell lung cancer. Lung cancer. 78:153–160.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fibla JJ, Cassivi SD, Brunelli A, Decker
PA, Allen MS, Darling GE, Landreneau RJ and Putnam JB:
Re-evaluation of the prognostic value of visceral pleura invasion
in Stage IB non-small cell lung cancer using the prospective
multicenter ACOSOG Z0030 trial data set. Lung cancer. 78:259–262.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Takizawa T, Terashima M, Koike T, Watanabe
T, Kurita Y, Yokoyama A and Honma K: Lymph node metastasis in small
peripheral adenocarcinoma of the lung. J Thorac Cardiovasc Surg.
116:276–280. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kang JH, Kim KD and Chung KY: Prognostic
value of visceral pleura invasion in non-small cell lung cancer.
Eur J Cardiothorac Surg. 23:865–869. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hirsch FR, Scagliotti GV, Langer CJ,
Varella-Garcia M and Franklin WA: Epidermal growth factor family of
receptors in preneoplasia and lung cancer: Perspectives for
targeted therapies. Lung cancer. 1 41 Suppl:S29–S42. 2003.
View Article : Google Scholar
|
|
18
|
Kazandjian D, Blumenthal GM, Yuan W, He K,
Keegan P and Pazdur R: FDA approval of gefitinib for the treatment
of patients with metastatic EGFR mutation-positive non-small cell
lung cancer. Clin Cancer Res. 22:1307–1312. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dacic S, Shuai Y, Yousem S, Ohori P and
Nikiforova M: Clinicopathological predictors of EGFR/KRAS
mutational status in primary lung adenocarcinomas. Mod Pathol.
23:159–168. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ikeda K, Nomori H, Ohba Y, Shibata H, Mori
T, Honda Y, Iyama K and Kobayashi T: Epidermal growth factor
receptor mutations in multicentric lung adenocarcinomas and
atypical adenomatous hyperplasias. J Thorac Oncol. 3:467–471. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tsai MF, Chang TH, Wu SG, Yang HY, Hsu YC,
Yang PC and Shih JY: EGFR-L858R mutant enhances lung adenocarcinoma
cell invasive ability and promotes malignant pleural effusion
formation through activation of the CXCL12-CXCR4 pathway. Sci Rep.
5:135742015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shi X, Wu H, Lu J, Duan H, Liu X and Liang
Z: Screening for major driver oncogene alterations in adenosquamous
lung carcinoma using PCR coupled with next-generation and Sanger
sequencing methods. Sci Rep. 6:222972016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang Y, Shi C, Sun H, Yin W, Zhou X, Zhang
L and Jiang G: Elderly male smokers with right lung tumors are
viable candidates for KRAS mutation screening. Sci Rep.
6:185662016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gasparini P, Cascione L, Landi L, Carasi
S, Lovat F, Tibaldi C, Alì G, D'Incecco A, Minuti G, Chella A, et
al: microRNA classifiers are powerful diagnostic/prognostic tools
in ALK-, EGFR-, and KRAS-driven lung cancers. Proc Natl Acad Sci
USA. 112:pp. 14924–14929. 2015, View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Song Q, Xu Y, Yang C, Chen Z, Jia C, Chen
J, Zhang Y, Lai P, Fan X, Zhou X, et al: miR-483-5p promotes
invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1
and ALCAM. Cancer Res. 74:3031–3042. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fan C, Lin Y, Mao Y, Huang Z, Liu AY, Ma
H, Yu D, Maitikabili A, Xiao H, Zhang C, et al: MicroRNA-543
suppresses colorectal cancer growth and metastasis by targeting
KRAS, MTA1 and HMGA2. Oncotarget. 7:21825–21839. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang WB, Chen PH, Hsu T I, Fu TF, Su WC,
Liaw H, Chang WC and Hung JJ: Sp1-mediated microRNA-182 expression
regulates lung cancer progression. Oncotarget. 5:740–753. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Valeri N, Braconi C, Gasparini P, Murgia
C, Lampis A, Paulus-Hock V, Hart JR, Ueno L, Grivennikov SI, Lovat
F, et al: MicroRNA-135b promotes cancer progression by acting as a
downstream effector of oncogenic pathways in colon cancer. Cancer
cell. 25:469–483. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nagel R, le Sage C, Diosdado B, van der
Waal M, Vrielink Oude JA, Bolijn A, Meijer GA and Agami R:
Regulation of the adenomatous polyposis coli gene by the miR-135
family in colorectal cancer. Cancer Res. 68:5795–5802. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li Y, Xu D, Bao C, Zhang Y, Chen D, Zhao
F, Ding J, Liang L, Wang Q, Liu L, et al: MicroRNA-135b, a HSF1
target, promotes tumor invasion and metastasis by regulating RECK
and EVI5 in hepatocellular carcinoma. Oncotarget. 6:2421–2433.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang L, Sun ZJ, Bian Y and Kulkarni AB:
MicroRNA-135b acts as a tumor promoter by targeting the
hypoxia-inducible factor pathway in genetically defined mouse model
of head and neck squamous cell carcinoma. Cancer Lett. 331:230–238.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu W, Wang Z, Yang P, Yang J, Liang J,
Chen Y, Wang H, Wei G, Ye S and Zhou Y: MicroRNA-135b regulates
metastasis suppressor 1 expression and promotes migration and
invasion in colorectal cancer. Mol Cell Biochem. 388:249–259. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Agalioti T, Giannou AD and Stathopoulos
GT: Pleural involvement in lung cancer. J Thorac Dis. 7:1021–1030.
2015.PubMed/NCBI
|
|
36
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ,
Van Schil PE, et al: International association for the study of
lung cancer/american thoracic society/european respiratory society
international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kadota K, Villena-Vargas J, Yoshizawa A,
Motoi N, Sima CS, Riely GJ, Rusch VW, Adusumilli PS and Travis WD:
Prognostic significance of adenocarcinoma in situ, minimally
invasive adenocarcinoma, and nonmucinous lepidic predominant
invasive adenocarcinoma of the lung in patients with stage I
disease. Am J Surg Pathol. 38:448–460. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yoshizawa A, Motoi N, Riely GJ, Sima CS,
Gerald WL, Kris MG, Park BJ, Rusch VW and Travis WD: Impact of
proposed IASLC/ATS/ERS classification of lung adenocarcinoma:
Prognostic subgroups and implications for further revision of
staging based on analysis of 514 stage I cases. Mod Pathol.
24:653–664. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tsuta K, Kawago M, Inoue E, Yoshida A,
Takahashi F, Sakurai H, Watanabe S, Takeuchi M, Furuta K, Asamura H
and Tsuda H: The utility of the proposed IASLC/ATS/ERS lung
adenocarcinoma subtypes for disease prognosis and correlation of
driver gene alterations. Lung cancer. 81:371–376. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cagle PT, Allen TC, Dacic S, Beasley MB,
Borczuk AC, Chirieac LR, Laucirica R, Ro JY and Kerr KM: Revolution
in lung cancer: New challenges for the surgical pathologist. Arch
Pathol Lab Med. 135:110–116. 2011.PubMed/NCBI
|
|
42
|
Eto T, Suzuki H, Honda A and Nagashima Y:
The changes of the stromal elastotic framework in the growth of
peripheral lung adenocarcinomas. Cancer. 77:646–656. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nakanishi H, Matsumoto S, Iwakawa R, Kohno
T, Suzuki K, Tsuta K, Matsuno Y, Noguchi M, Shimizu E and Yokota J:
Whole genome comparison of allelic imbalance between noninvasive
and invasive small-sized lung adenocarcinomas. Cancer Res.
69:1615–1623. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Clay TD, Russell PA, Do H, Sundararajan V,
Conron M, Wright GM, Dobrovic A, Moore MM and McLachlan SA:
Associations between the IASLC/ATS/ERS lung adenocarcinoma
classification and EGFR and KRAS mutations. Pathology. 48:17–24.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yatabe Y, Takahashi T and Mitsudomi T:
Epidermal growth factor receptor gene amplification is acquired in
association with tumor progression of EGFR-mutated lung cancer.
Cancer Res. 68:2106–2111. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kadota K, Yeh YC, D'Angelo SP, Moreira AL,
Kuk D, Sima CS, Riely GJ, Arcila ME, Kris MG, Rusch VW, et al:
Associations between mutations and histologic patterns of mucin in
lung adenocarcinoma: Invasive mucinous pattern and extracellular
mucin are associated with KRAS mutation. Am J Surg Pathol.
38:1118–1127. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Soh J, Toyooka S, Ichihara S, Asano H,
Kobayashi N, Suehisa H, Otani H, Yamamoto H, Ichimura K, Kiura K,
et al: Sequential molecular changes during multistage pathogenesis
of small peripheral adenocarcinomas of the lung. J Thorac Oncol.
3:340–347. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yoshida Y, Shibata T, Kokubu A, Tsuta K,
Matsuno Y, Kanai Y, Asamura H, Tsuchiya R and Hirohashi S:
Mutations of the epidermal growth factor receptor gene in atypical
adenomatous hyperplasia and bronchioloalveolar carcinoma of the
lung. Lung cancer. 50:1–8. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Han HS, Eom DW, Kim JH, Kim KH, Shin HM,
An JY, Lee KM, Choe KH, Lee KH, Kim ST, et al: EGFR mutation status
in primary lung adenocarcinomas and corresponding metastatic
lesions: Discordance in pleural metastases. Clin Lung Cancer.
12:380–386. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Mok T, Wu YL and Zhang L: A small step
towards personalized medicine for non-small cell lung cancer.
Discov Med. 8:227–231. 2009.PubMed/NCBI
|
|
51
|
Mitsudomi T and Yatabe Y: Mutations of the
epidermal growth factor receptor gene and related genes as
determinants of epidermal growth factor receptor tyrosine kinase
inhibitors sensitivity in lung cancer. Cancer Sci. 98:1817–1824.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Alvarez JV, Greulich H, Sellers WR,
Meyerson M and Frank DA: Signal transducer and activator of
transcription 3 is required for the oncogenic effects of
non-small-cell lung cancer-associated mutations of the epidermal
growth factor receptor. Cancer Res. 66:3162–3168. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Matsuyama H, Suzuki HI, Nishimori H,
Noguchi M, Yao T, Komatsu N, Mano H, Sugimoto K and Miyazono K:
miR-135b mediates NPM-ALK-driven oncogenicity and renders
IL-17-producing immunophenotype to anaplastic large cell lymphoma.
Blood. 118:6881–6892. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Takata S, Takigawa N, Segawa Y, Kubo T,
Ohashi K, Kozuki T, Teramoto N, Yamashita M, Toyooka S, Tanimoto M
and Kiura K: STAT3 expression in activating EGFR-driven
adenocarcinoma of the lung. Lung Cancer. 75:24–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Khatri R and Subramanian S: MicroRNA-135b
and its circuitry networks as potential therapeutic targets in
colon cancer. Front Oncol. 3:2682013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Shimizu K, Yoshida J, Nagai K, Nishimura
M, Ishii G, Morishita Y and Nishiwaki Y: Visceral pleural invasion
is an invasive and aggressive indicator of non-small cell lung
cancer. J Thorac Cardiovasc Surg. 130:160–165. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Riquet M, Badoual C, Le Pimpec Barthes F,
Lhote FM, Souilamas R, Hubsch JP and Danel C: Visceral pleura
invasion and pleural lavage tumor cytology by lung cancer: A
prospective appraisal. Ann Thorac Surg. 75:353–355. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Butnor KJ and Cooper K: Visceral pleural
invasion in lung cancer: Recognizing histologic parameters that
impact staging and prognosis. Adv Anat Pathol. 12:1–6. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zou J, Bella AE, Chen Z, Han X, Su C, Lei
Y and Luo H: Frequency of EGFR mutations in lung adenocarcinoma
with malignant pleural effusion: Implication of cancer biological
behaviour regulated by EGFR mutation. J Int Med Res. 42:1110–1117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Raparia K, Villa C, Raj R and Cagle PT:
Peripheral lung adenocarcinomas with KRAS mutations are more likely
to invade visceral pleura. Arch Pathol Lab Med. 139:189–193. 2015.
View Article : Google Scholar : PubMed/NCBI
|
